Researchers pinpoint a cellular process called 'clonal hematopoiesis' as a new risk factor for cardiovascular problems. In ...

Achilles Therapeutics has announced it will discontinue its tumor-infiltrating lymphocyte (TIL)-based clonal neoantigen T ...

A new study has settled a prolonged dispute within the medical community by showing that mutations associated with clonal ...

A type of zooplankton, Daphnia pulex (a.k.a. the water flea) is a microscopic crustacean whose unique reproduction habits ...

Antibiotics are a lifesaving tool. Yet, due to their chronic overuse, microbes are evolving and developing immunity against ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Achilles to discontinue development of TIL-based cNeT therapy––Cash position of $95.1 million as of June 30, 2024––BofA Securities engaged to ...

Cancer cells are driven by the same imperative guiding all living things: to grow, survive and reproduce. Although cancer's ...

Shares of Achilles Therapeutics plc (NASDAQ:ACHL) surged Thursday after the biotechnology firm revealed plans to discontinue ...

A new review by Arizona State University researcher Carlo Maley and Lucie Laplane from the University of Paris ...

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...

(RTTNews) - Achilles Therapeutics plc (ACHL) Thursday announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials.